ADVM stock forecast
Our latest prediction for Adverum Biotechnologies Inc's stock price was made on the May 17, 2022 when the stock price was at 0.83$.
In the short term (2weeks), ADVM's stock price should outperform the market by 3.92%. During that period the price should oscillate between -11.57% and +22.37%.
In the medium term (3months), ADVM's stock price should outperform the market by 24.75%. During that period the price should oscillate between -39.19% and +67.60%.Get email alerts
Create a solid portfolio with ADVM
About Adverum Biotechnologies Inc
Adverum Biotechnologies is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema.
At the moment the company generates 99M USD in revenues.
On its last earning announcement, the company reported a loss of -1.66$ per share.
The book value per share is 3.72$
Three months stock forecastMay 17, 2022
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|